Moderna reports on successful development of variant-specific updates to its vaccine.

Dr. Barry Dworkin

Medical Mythbusting Commentary for April 20, 2022

Moderna reports on successful development of variant-specific updates to its vaccine. Play Now | Play in Popup | Download

Source:
Moderna says new booster plus original shot provides better COVID-19 protection

Related posts:

  1. CDC and other regulators working to assess risk and if there is a causal relationship between mRNA vaccines and myo/pericarditis seen predominately in a small number of males 16-24 years old after 2nd dose.
  2. Retracted Canadian study that reported 1/1000 risk of myocarditis from mRNA vaccine weaponized by anti-vaccination websites despite data correction by the authors to 1/25,000. Review system worked to uncover error but damage now done.
  3. Sweden suspends Moderna vaccine but keeps Pfizer for under 30’s citing unpublished nor peer reviewed data on the “very small” risk of vaccine-induced myocarditis. Previous research reported COVID poses 5-10 times greater risk than vaccine.
  4. Moderna CEO states fourth/yearly booster may be needed. We need credible independent sources to review the evidence to determine if cellular immunity will provide longer term protection mitigating booster frequency.
Bitnami